Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:COGT NASDAQ:IMVT NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$10.56+1.8%$7.30$2.25▼$11.65$1.40B2.396.27 million shs7.03 million shsCOGTCogent Biosciences$31.36-4.0%$35.69$4.55▼$43.73$5.58B0.371.43 million shs1.67 million shsIMVTImmunovant$26.53-3.5%$26.30$13.79▼$30.16$5.60B0.71.41 million shs1.28 million shsXENEXenon Pharmaceuticals$53.71-1.3%$56.30$28.19▼$63.95$5.26B0.65942,069 shs676,957 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways+1.83%+9.43%+58.56%+38.40%+165.33%COGTCogent Biosciences-4.04%-8.04%-15.81%-16.64%+542.62%IMVTImmunovant-3.49%-8.71%-9.45%+0.95%+83.47%XENEXenon Pharmaceuticals-1.25%-3.71%-10.03%+28.92%+77.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCompass Pathways$10.56+1.8%$7.30$2.25▼$11.65$1.40B2.396.27 million shs7.03 million shsCOGTCogent Biosciences$31.36-4.0%$35.69$4.55▼$43.73$5.58B0.371.43 million shs1.67 million shsIMVTImmunovant$26.53-3.5%$26.30$13.79▼$30.16$5.60B0.71.41 million shs1.28 million shsXENEXenon Pharmaceuticals$53.71-1.3%$56.30$28.19▼$63.95$5.26B0.65942,069 shs676,957 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCompass Pathways+1.83%+9.43%+58.56%+38.40%+165.33%COGTCogent Biosciences-4.04%-8.04%-15.81%-16.64%+542.62%IMVTImmunovant-3.49%-8.71%-9.45%+0.95%+83.47%XENEXenon Pharmaceuticals-1.25%-3.71%-10.03%+28.92%+77.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCompass Pathways 2.92Moderate Buy$20.5894.92% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7339.44% UpsideIMVTImmunovant 2.45Hold$32.4422.29% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.0743.49% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, IMVT, COGT, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CMPSCompass Pathways Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $20.005/14/2026CMPSCompass Pathways Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $17.005/14/2026CMPSCompass Pathways Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $22.005/13/2026CMPSCompass Pathways BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.005/12/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $80.005/10/2026XENEXenon Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$69.005/8/2026XENEXenon Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $82.005/8/2026XENEXenon Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $78.005/7/2026CMPSCompass Pathways UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$18.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.005/5/2026CMPSCompass Pathways Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/ACOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/AIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AXENEXenon Pharmaceuticals$7.50M692.29N/AN/A$7.53 per share7.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)IMVTImmunovant-$413.84M-$2.69N/AN/AN/AN/A-63.17%-58.01%5/20/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%N/ALatest CMPS, IMVT, COGT, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60N/AN/AN/AN/AN/A5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A3/24/2026Q4 2025CMPSCompass Pathways-$0.41-$1.00-$0.59-$1.00N/AN/A2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCompass PathwaysN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCompass Pathways0.153.323.32COGTCogent Biosciences0.4115.1415.14IMVTImmunovantN/A15.7415.74XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCompass Pathways46.19%COGTCogent BiosciencesN/AIMVTImmunovant47.08%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCMPSCompass Pathways2.82%COGTCogent Biosciences7.29%IMVTImmunovant1.80%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableCOGTCogent Biosciences80170.87 million158.41 millionOptionableIMVTImmunovant120203.53 million199.87 millionOptionableXENEXenon Pharmaceuticals21096.67 million92.73 millionOptionableCMPS, IMVT, COGT, and XENE HeadlinesRecent News About These CompaniesDNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENEMay 18 at 3:44 AM | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comStock Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)May 14, 2026 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00 at JPMorgan Chase & Co.May 12, 2026 | marketbeat.comEquities Analysts Set Expectations for XENE Q2 EarningsMay 12, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Sells 35,973 Shares of Xenon Pharmaceuticals Inc. $XENEMay 12, 2026 | marketbeat.comA Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash RunwayMay 11, 2026 | finance.yahoo.comDid Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?May 11, 2026 | finance.yahoo.comNan Fung Trinity HK Ltd. Has $10.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEMay 10, 2026 | marketbeat.comXenon Pharmaceuticals Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comXenon Highlights Positive Phase 3 Azetukalner Seizure DataMay 8, 2026 | theglobeandmail.comXenon Q1 earnings match estimates, pipeline development in focusMay 8, 2026 | msn.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysMay 8, 2026 | marketbeat.comNeedham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $78.00May 8, 2026 | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2026 | finance.yahoo.comXenon (XENE) Q1 2026 Earnings TranscriptMay 7, 2026 | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comXenon Reports Q1 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comXenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026May 7, 2026 | globenewswire.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026This 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026CMPS, IMVT, COGT, and XENE Company DescriptionsCompass Pathways NASDAQ:CMPS$10.56 +0.19 (+1.83%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$10.66 +0.10 (+0.95%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Cogent Biosciences NASDAQ:COGT$31.36 -1.32 (-4.04%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$31.43 +0.07 (+0.22%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Immunovant NASDAQ:IMVT$26.53 -0.96 (-3.49%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$26.53 0.00 (0.00%) As of 09:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Xenon Pharmaceuticals NASDAQ:XENE$53.71 -0.68 (-1.25%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$53.60 -0.11 (-0.20%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
